Zydus Lifesciences gets USFDA nod for generic acne-treating drug
The approval granted by the US Food and Drug Administration (USFDA) is for Minocycline Hydrochloride extended-release tablets of strengths 55 mg, 65 mg, and 115 mg, Zydus Lifesciences said in a regulatory filing.
Zydus Lifesciences on Monday said it has received final approval from the US health regulator for its generic antibiotic Minocycline Hydrochloride extended-release tablets used for treatment of moderate to severe acne.
The approval granted by the US Food and Drug Administration (USFDA) is for Minocycline Hydrochloride extended-release tablets of strengths 55 mg, 65 mg, and 115 mg, Zydus Lifesciences said in a regulatory filing.
The tablet is used for treatment of moderate to severe acne in people aged 12 years and above.
The product will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad, the company said.
Catch latest stock market updates here. For all other news related to business, politics, tech, sports and auto, visit Zeebiz.com.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Power of Rs 2,000 Monthly SIP: Can one achieve Rs 3.18 crore corpus by investing Rs 2,000 monthly? If yes, in how many years
SIP+SWP Calculator: Rs 12,000 monthly SIP for 25 years and then Rs 135,000 monthly income for 30 years; how it can work out
Stocks to buy for 15 days: Analysts bullish on these 2 largecap, 2 midcap, 1 smallcap scrips - Check targets
Latest FD Interest Rates: What SBI, PNB, HDFC Bank, ICICI Bank and other banks are offering in 3-year fixed deposit schemes
SBI Senior Citizen FD Interest Rates: Know how Rs 5 lakh, Rs 10 lakh, and Rs 15 lakh investments will give in maturity in Amrit Vrishti, 1-, 3-, and 5-year fixed deposit schemes
Home Loan Calculator: How 10% prepayment of Rs 85 lakh, 25-year loan can save Rs 40.23 lakh and 65 months; see calculations
Top 7 Flexi Cap Mutual Funds With Best SIP Returns in 5 Years: Rs 15,000 monthly SIP investment in No. 1 scheme has jumped to Rs 19,07,364
Top 7 ETFs That Have Given up to 59% Returns in 1 Year: No. 1 ETF has turned Rs 3 lakh investment into Rs 4.65 lakh; know about others too
04:58 PM IST